Cardiol Therapeutics AGM Results Highlight Strong Shareholder Support
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: PRnewswire
- Shareholder Voting Results: At the AGM held on June 24, 2026, Cardiol Therapeutics received overwhelming shareholder support for all management resolutions, including the election of board members, with the highest approval rate reaching 99.19%, indicating strong confidence in the company's strategic direction.
- Director Election Performance: In the board elections, Dr. Timothy Garnett received 99.19% support, while David Elsley and Chris Waddick garnered 98.11% and 98.96% respectively, reflecting the trust and backing of the leadership in advancing heart disease treatments.
- Clinical Trial Progress: The ongoing MAVERIC and ARCHER programs for CardiolRx™ target recurrent pericarditis and acute myocarditis, showcasing the company's commitment to innovation and clinical research in heart disease, which is expected to drive future market growth.
- New Drug Development Strategy: Cardiol Therapeutics is developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, which is anticipated to further expand its market share in the heart disease sector and meet the growing healthcare demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRDL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRDL
Wall Street analysts forecast CRDL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.070
Low
8.00
Averages
8.50
High
9.00
Current: 1.070
Low
8.00
Averages
8.50
High
9.00
No data
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiol Therapeutics AGM Results Highlight Strong Shareholder Support
- Shareholder Voting Results: At the AGM held on June 24, 2026, Cardiol Therapeutics received overwhelming shareholder support for all management resolutions, including the election of board members, with the highest approval rate reaching 99.19%, indicating strong confidence in the company's strategic direction.
- Director Election Performance: In the board elections, Dr. Timothy Garnett received 99.19% support, while David Elsley and Chris Waddick garnered 98.11% and 98.96% respectively, reflecting the trust and backing of the leadership in advancing heart disease treatments.
- Clinical Trial Progress: The ongoing MAVERIC and ARCHER programs for CardiolRx™ target recurrent pericarditis and acute myocarditis, showcasing the company's commitment to innovation and clinical research in heart disease, which is expected to drive future market growth.
- New Drug Development Strategy: Cardiol Therapeutics is developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, which is anticipated to further expand its market share in the heart disease sector and meet the growing healthcare demands.
See More
Cardiol Therapeutics Announces AGM Results
- Election Results: During the AGM held on June 24, 2026, shareholders overwhelmingly elected directors including Dr. Guillermo Torre-Amione and David Elsley with support ranging from 96.45% to 99.19%, reflecting strong trust in management and enhancing the stability of the company's governance structure.
- Auditor Appointment: Shareholders unanimously approved the appointment of BDO Canada LLP as the company's auditors, granting the board authority to determine their remuneration, a move that will ensure financial transparency and compliance, thereby boosting investor confidence.
- Clinical Research Progress: Cardiol Therapeutics is advancing its clinical trials for CardiolRx™, particularly the pivotal Phase III MAVERIC trial for recurrent pericarditis, which is expected to bring new breakthroughs in heart disease treatment, addressing the urgent market demand for innovative therapies.
- New Drug Development Plans: The company is also developing CRD-38, a novel subcutaneous formulation for treating inflammatory heart disease, which is anticipated to fill a market gap and meet the demand for heart disease-related healthcare costs exceeding $30 billion annually.
See More
Cardiol Therapeutics to Host 2026 Annual General Meeting
- AGM Announcement: Cardiol Therapeutics will hold its virtual Annual General Meeting on June 24, 2026, at 4:30 p.m. EDT, allowing global shareholders to participate and vote via live webcast, enhancing shareholder engagement.
- Drug Development Progress: The company's lead small-molecule candidate, CardiolRx™, is currently undergoing a pivotal Phase III trial for recurrent pericarditis, with FDA granting Orphan Drug Designation, indicating significant potential in heart disease treatment.
- New Drug Development: Cardiol is also developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart diseases, including heart failure, which is expected to significantly improve patient quality of life and reduce healthcare costs.
- Market Outlook: With heart disease being a leading cause of death and hospitalization in developed countries, incurring over $30 billion in annual healthcare costs in the U.S., Cardiol's innovative therapies are poised to capture a significant share of this substantial market.
See More
Cardiol Therapeutics to Host 2026 Annual General Meeting
- AGM Announcement: Cardiol Therapeutics will hold its virtual Annual General Meeting on June 24, 2026, at 4:30 p.m. EDT, aiming to enhance shareholder engagement and transparency through a live webcast format.
- Clinical Trial Progress: The lead drug candidate, CardiolRx™, is currently undergoing a pivotal Phase III trial for recurrent pericarditis, with the FDA granting Orphan Drug Designation, indicating the company's potential in heart disease treatment.
- New Drug Development: The company is developing CRD-38, a novel subcutaneous formulation intended for inflammatory heart disease treatment, including heart failure, which is expected to significantly improve patient quality of life and reduce healthcare costs.
- Market Outlook: Heart disease is a leading cause of death in developed countries, with associated healthcare costs exceeding $30 billion annually in the U.S., positioning Cardiol's innovative therapies to capture a significant share of this vast market.
See More
Cardiol Therapeutics to Participate in Investor Conference
- Investor Conference Participation: Cardiol Therapeutics will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its latest advancements in heart disease treatment, which is expected to attract investor interest.
- Clinical Trial Progress: The company's lead small-molecule drug candidate, CardiolRx™, is undergoing a pivotal Phase III trial for recurrent pericarditis, with FDA granting Orphan Drug Designation, indicating its potential in heart disease treatment and possibly enhancing the company's market position in the biopharmaceutical sector.
- New Drug Development: Cardiol is also developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, including heart failure, which is a leading cause of death and hospitalization in developed countries, with associated healthcare costs exceeding $30 billion annually, highlighting significant market demand.
- Forward-Looking Information Statement: The press release contains forward-looking information, emphasizing the company's focus on heart disease treatment and future clinical research plans, urging investors to approach this information cautiously to avoid over-reliance on future performance expectations.
See More
Cardiol Therapeutics Advances Heart Disease Treatment with CardiolRx™
- Clinical Study Results: Cardiol Therapeutics' Phase II study results indicate that CardiolRx™ significantly reduces pericarditis pain and inflammation in patients with a high baseline disease burden, supporting its further development in the Phase III MAVERIC trial.
- Safety and Tolerability: The study demonstrates that CardiolRx™ has a favorable safety and tolerability profile, significantly reducing the number of pericarditis episodes per year, highlighting its potential as a non-immunosuppressive therapy to meet urgent patient needs.
- Trial Progress: The MAVERIC trial has surpassed 75% enrollment, establishing a solid foundation for the clinical application of CardiolRx™, which is expected to provide more effective treatment options for heart disease patients.
- Independent Validation: The upcoming publication in JAHA provides independent validation of the Phase II study results, further emphasizing the significance of CardiolRx™ in heart disease treatment and its potential to transform existing therapeutic approaches.
See More
Cardiol Therapeutics AGM Results Highlight Strong Shareholder Support
- Shareholder Voting Results: At the AGM held on June 24, 2026, Cardiol Therapeutics received overwhelming shareholder support for all management resolutions, including the election of board members, with the highest approval rate reaching 99.19%, indicating strong confidence in the company's strategic direction.
- Director Election Performance: In the board elections, Dr. Timothy Garnett received 99.19% support, while David Elsley and Chris Waddick garnered 98.11% and 98.96% respectively, reflecting the trust and backing of the leadership in advancing heart disease treatments.
- Clinical Trial Progress: The ongoing MAVERIC and ARCHER programs for CardiolRx™ target recurrent pericarditis and acute myocarditis, showcasing the company's commitment to innovation and clinical research in heart disease, which is expected to drive future market growth.
- New Drug Development Strategy: Cardiol Therapeutics is developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, which is anticipated to further expand its market share in the heart disease sector and meet the growing healthcare demands.
See More
Cardiol Therapeutics Announces AGM Results
- Election Results: During the AGM held on June 24, 2026, shareholders overwhelmingly elected directors including Dr. Guillermo Torre-Amione and David Elsley with support ranging from 96.45% to 99.19%, reflecting strong trust in management and enhancing the stability of the company's governance structure.
- Auditor Appointment: Shareholders unanimously approved the appointment of BDO Canada LLP as the company's auditors, granting the board authority to determine their remuneration, a move that will ensure financial transparency and compliance, thereby boosting investor confidence.
- Clinical Research Progress: Cardiol Therapeutics is advancing its clinical trials for CardiolRx™, particularly the pivotal Phase III MAVERIC trial for recurrent pericarditis, which is expected to bring new breakthroughs in heart disease treatment, addressing the urgent market demand for innovative therapies.
- New Drug Development Plans: The company is also developing CRD-38, a novel subcutaneous formulation for treating inflammatory heart disease, which is anticipated to fill a market gap and meet the demand for heart disease-related healthcare costs exceeding $30 billion annually.
See More
Cardiol Therapeutics to Host 2026 Annual General Meeting
- AGM Announcement: Cardiol Therapeutics will hold its virtual Annual General Meeting on June 24, 2026, at 4:30 p.m. EDT, allowing global shareholders to participate and vote via live webcast, enhancing shareholder engagement.
- Drug Development Progress: The company's lead small-molecule candidate, CardiolRx™, is currently undergoing a pivotal Phase III trial for recurrent pericarditis, with FDA granting Orphan Drug Designation, indicating significant potential in heart disease treatment.
- New Drug Development: Cardiol is also developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart diseases, including heart failure, which is expected to significantly improve patient quality of life and reduce healthcare costs.
- Market Outlook: With heart disease being a leading cause of death and hospitalization in developed countries, incurring over $30 billion in annual healthcare costs in the U.S., Cardiol's innovative therapies are poised to capture a significant share of this substantial market.
See More
Cardiol Therapeutics to Host 2026 Annual General Meeting
- AGM Announcement: Cardiol Therapeutics will hold its virtual Annual General Meeting on June 24, 2026, at 4:30 p.m. EDT, aiming to enhance shareholder engagement and transparency through a live webcast format.
- Clinical Trial Progress: The lead drug candidate, CardiolRx™, is currently undergoing a pivotal Phase III trial for recurrent pericarditis, with the FDA granting Orphan Drug Designation, indicating the company's potential in heart disease treatment.
- New Drug Development: The company is developing CRD-38, a novel subcutaneous formulation intended for inflammatory heart disease treatment, including heart failure, which is expected to significantly improve patient quality of life and reduce healthcare costs.
- Market Outlook: Heart disease is a leading cause of death in developed countries, with associated healthcare costs exceeding $30 billion annually in the U.S., positioning Cardiol's innovative therapies to capture a significant share of this vast market.
See More
Cardiol Therapeutics to Participate in Investor Conference
- Investor Conference Participation: Cardiol Therapeutics will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its latest advancements in heart disease treatment, which is expected to attract investor interest.
- Clinical Trial Progress: The company's lead small-molecule drug candidate, CardiolRx™, is undergoing a pivotal Phase III trial for recurrent pericarditis, with FDA granting Orphan Drug Designation, indicating its potential in heart disease treatment and possibly enhancing the company's market position in the biopharmaceutical sector.
- New Drug Development: Cardiol is also developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, including heart failure, which is a leading cause of death and hospitalization in developed countries, with associated healthcare costs exceeding $30 billion annually, highlighting significant market demand.
- Forward-Looking Information Statement: The press release contains forward-looking information, emphasizing the company's focus on heart disease treatment and future clinical research plans, urging investors to approach this information cautiously to avoid over-reliance on future performance expectations.
See More
Cardiol Therapeutics Advances Heart Disease Treatment with CardiolRx™
- Clinical Study Results: Cardiol Therapeutics' Phase II study results indicate that CardiolRx™ significantly reduces pericarditis pain and inflammation in patients with a high baseline disease burden, supporting its further development in the Phase III MAVERIC trial.
- Safety and Tolerability: The study demonstrates that CardiolRx™ has a favorable safety and tolerability profile, significantly reducing the number of pericarditis episodes per year, highlighting its potential as a non-immunosuppressive therapy to meet urgent patient needs.
- Trial Progress: The MAVERIC trial has surpassed 75% enrollment, establishing a solid foundation for the clinical application of CardiolRx™, which is expected to provide more effective treatment options for heart disease patients.
- Independent Validation: The upcoming publication in JAHA provides independent validation of the Phase II study results, further emphasizing the significance of CardiolRx™ in heart disease treatment and its potential to transform existing therapeutic approaches.
See More
